Clinical Trials Logo
  1. Home
  2. Cholestasis
  3. NCT00969332

A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease — FO  

Cholestasis Clinical Trial

Official title:
Omegaven and Parenteral Nutrition Associated Cholestasis

Clinical Trial Summary

The purpose of the study is to investigate if intravenous fish oil, commercially available as Omegaven, safely and effectively reverses parenteral nutrition associated cholestasis in children.

Clinical Trial Description

Infants dependent on parenteral nutrition for greater than 1 year who develop parenteral nutrition associated cholestasis will universally face mortality unless they receive a timely liver and/or small bowel transplant. Although transplant survival has improved in recent years, survival is not guaranteed, and transplant care remains costly. Alternative nutritional and pharmacological strategies are imperative to improve the clinical outcomes of infants with intestinal failure and parenteral nutrition associated cholestasis. In both animal and human studies, intravenous fish oil, a lipid emulsion rich in omega-3 fatty acids and Vitamin E, and lacking phytosterols, has been shown to ameliorate parenteral nutrition associated cholestasis and improve morbidity and mortality. The purpose of this pilot study is to investigate if Omegaven, a commercially available intravenous fish oil, at 1 g/kg/d, will safely reverse liver disease in 80 subjects with parenteral nutrition associated cholestasis. Subjects can initially receive a maximum of 6 months (24 weeks) of intravenous fish oil. If the subject re-develops liver disease and still satisfies inclusion/exclusion criteria, the intervention can be restarted. Study subjects will be compared to a historical cohort of children with Short Bowel Syndrome and parenteral nutrition associated cholestasis who have been receiving standard intravenous soybean oil for > 60 days. The fish oil cohort will be followed for a total of 5 years to determine if transplant-free mortality is reduced. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00969332
Study type Interventional
Source University of California, Los Angeles
Contact
Status Terminated
Phase Phase 2
Start date August 2009
Completion date February 12, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Completed NCT00738101 - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants N/A
Completed NCT00004414 - Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis N/A
Completed NCT03662282 - Omegaven as Alternative Parenteral Fat Nutrition Phase 3
Recruiting NCT02334293 - Omegaven® as Parenteral Nutrition N/A
Recruiting NCT01252043 - Retrospective Review of CT and MR in Pediatric Patients With Cholestasis N/A
Completed NCT00846963 - Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates Phase 2/Phase 3
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Completed NCT01194063 - Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Phase 3
Recruiting NCT01998620 - Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Phase 4
Completed NCT00080236 - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation Phase 2
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3
Active, not recruiting NCT00004315 - Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease Phase 2
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Terminated NCT02267707 - Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Phase 1
Completed NCT02357576 - Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD Phase 3
Completed NCT02721277 - SMOFlipid to Lessen the Severity of Neonatal Cholestasis Phase 1/Phase 2
Terminated NCT02767648 - Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region N/A